Cempra Inc (CEMP) 21.94 $CEMP
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - 1 hr 35 mins ago
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences.
CEMP: 21.94 (+0.50)
Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
GlobeNewswire - Tue Aug 30, 8:15AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Antimicrobial Drugs Advisory Committee on November 4, 2016 in Silver Spring, Maryland to discuss the safety and efficacy of solithromycin to treat community-acquired bacterial pneumonia (CABP).
CEMP: 21.94 (+0.50)
Cempra's Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
GlobeNewswire - Thu Aug 25, 3:05PM CDT
-- Both pivotal Phase 3 studies now published in leading infectious disease journals --
CEMP: 21.94 (+0.50)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 238.00 (+3.46), CEMP: 21.94 (+0.50), CORT: 5.33 (unch), PCRX: 39.63 (unch)
Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
GlobeNewswire - Tue Aug 23, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) seeking approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired bacterial pneumonia (CABP, also referred to as community-acquired pneumonia (CAP) in the EU).
CEMP: 21.94 (+0.50)
Cempra Appoints Dr. David Zaccardelli to Board of Directors
GlobeNewswire - Thu Aug 11, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the company has appointed David Zaccardelli, Pharm.D. to serve on the company's board of directors.
UTHR: 122.28 (unch), CEMP: 21.94 (+0.50)
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Aug 01, 3:05PM CDT
Current cash balance now expected to fund operations through 2017
CEMP: 21.94 (+0.50)
Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
GlobeNewswire - Mon Aug 01, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the company has appointed John Bluth to the newly created position of executive vice president, investor relations and corporate communications. He will report directly to Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.
CEMP: 21.94 (+0.50)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 42.02 (unch), JNJ: 119.34 (unch), GILD: 78.38 (unch), NVLS: 6.39 (unch), CYTR: 0.56 (-0.02), CEMP: 21.94 (+0.50), ACUR: 1.60 (+0.01), NVS: 78.77 (unch)
Cempra to Host Analyst and Investor Day on June 23, 2016
GlobeNewswire - Thu Jun 16, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, will host an Analyst and Investor Day on Thursday, June 23, 2016, from 8:30 a.m. to 11:30 a.m. EDT in New York City. Prabhavathi Fernandes, Ph.D., president and chief executive officer, and other members of the Cempra management team will provide a comprehensive update of commercialization plans for solithromycin in patients with community-acquired bacterial pneumonia (CABP), a review of the CABP market and need for new CABP drugs. In addition, notable physician experts will discuss their perspective on this disease and Cempa's pipeline of drug candidates.
CEMP: 21.94 (+0.50)
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that research findings for the company's lead product, solithromycin, will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston on June 16-20, 2016.
CEMP: 21.94 (+0.50)
Cempra to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2016 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 11:30 a.m. EDT on Thursday, June 9, 2016 in New York City.
CEMP: 21.94 (+0.50)
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
GlobeNewswire - Wed May 25, 3:30PM CDT
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM)
CEMP: 21.94 (+0.50)
Cempra to Present Solithromycin IV Data at ATS 2016
GlobeNewswire - Thu May 12, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2016, May 13-18, to be held in San Francisco.
CEMP: 21.94 (+0.50)
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Sun May 01, 4:00PM CDT
Solithromycin is designated by FDA as a Qualified Infectious Disease Product
CEMP: 21.94 (+0.50)
Cempra to Report First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report first quarter 2016 financial results before the open of U.S. financial markets on Monday, May 2, 2016. Cempra management will host a webcast and conference call at 8:00 a.m. ET that day to discuss the financial results and provide a corporate update.
CEMP: 21.94 (+0.50)
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.
CEMP: 21.94 (+0.50)
Cempra Reports Positive Data on Antibiotic Solithromycin
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 1:10PM CST
Cempra (CEMP) announced positive results from the phase III SOLITAIRE-ORAL study on solithromycin for the treatment of community-acquired bacterial pneumonia.
AGN: 238.00 (+3.46), LGND: 103.31 (-1.00), CEMP: 21.94 (+0.50), SNY: 38.47 (unch)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 238.00 (+3.46), AZN: 32.81 (unch), CEMP: 21.94 (+0.50), APHB: 1.70 (-0.01), GLPG: 54.30 (-0.55)
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra's Oral Solithromycin in Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Feb 05, 6:00AM CST
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone
CEMP: 21.94 (+0.50)
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - 1 hr 35 mins ago
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences.
CEMP: 21.94 (+0.50)
Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
GlobeNewswire - Tue Aug 30, 8:15AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Antimicrobial Drugs Advisory Committee on November 4, 2016 in Silver Spring, Maryland to discuss the safety and efficacy of solithromycin to treat community-acquired bacterial pneumonia (CABP).
CEMP: 21.94 (+0.50)
Cempra's Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
GlobeNewswire - Thu Aug 25, 3:05PM CDT
-- Both pivotal Phase 3 studies now published in leading infectious disease journals --
CEMP: 21.94 (+0.50)
Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 238.00 (+3.46), CEMP: 21.94 (+0.50), CORT: 5.33 (unch), PCRX: 39.63 (unch)
Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
GlobeNewswire - Tue Aug 23, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) seeking approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired bacterial pneumonia (CABP, also referred to as community-acquired pneumonia (CAP) in the EU).
CEMP: 21.94 (+0.50)
Cempra Appoints Dr. David Zaccardelli to Board of Directors
GlobeNewswire - Thu Aug 11, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the company has appointed David Zaccardelli, Pharm.D. to serve on the company's board of directors.
UTHR: 122.28 (unch), CEMP: 21.94 (+0.50)
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Aug 01, 3:05PM CDT
Current cash balance now expected to fund operations through 2017
CEMP: 21.94 (+0.50)
Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
GlobeNewswire - Mon Aug 01, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the company has appointed John Bluth to the newly created position of executive vice president, investor relations and corporate communications. He will report directly to Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.
CEMP: 21.94 (+0.50)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 42.02 (unch), JNJ: 119.34 (unch), GILD: 78.38 (unch), NVLS: 6.39 (unch), CYTR: 0.56 (-0.02), CEMP: 21.94 (+0.50), ACUR: 1.60 (+0.01), NVS: 78.77 (unch)
Cempra to Host Analyst and Investor Day on June 23, 2016
GlobeNewswire - Thu Jun 16, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, will host an Analyst and Investor Day on Thursday, June 23, 2016, from 8:30 a.m. to 11:30 a.m. EDT in New York City. Prabhavathi Fernandes, Ph.D., president and chief executive officer, and other members of the Cempra management team will provide a comprehensive update of commercialization plans for solithromycin in patients with community-acquired bacterial pneumonia (CABP), a review of the CABP market and need for new CABP drugs. In addition, notable physician experts will discuss their perspective on this disease and Cempa's pipeline of drug candidates.
CEMP: 21.94 (+0.50)
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that research findings for the company's lead product, solithromycin, will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston on June 16-20, 2016.
CEMP: 21.94 (+0.50)
Cempra to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2016 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 11:30 a.m. EDT on Thursday, June 9, 2016 in New York City.
CEMP: 21.94 (+0.50)
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
GlobeNewswire - Wed May 25, 3:30PM CDT
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM)
CEMP: 21.94 (+0.50)
Cempra to Present Solithromycin IV Data at ATS 2016
GlobeNewswire - Thu May 12, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the American Thoracic Society (ATS) International Conference 2016, May 13-18, to be held in San Francisco.
CEMP: 21.94 (+0.50)
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
GlobeNewswire - Sun May 01, 4:00PM CDT
Solithromycin is designated by FDA as a Qualified Infectious Disease Product
CEMP: 21.94 (+0.50)
Cempra to Report First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report first quarter 2016 financial results before the open of U.S. financial markets on Monday, May 2, 2016. Cempra management will host a webcast and conference call at 8:00 a.m. ET that day to discuss the financial results and provide a corporate update.
CEMP: 21.94 (+0.50)
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:30AM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 15th Annual Needham and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 1:40 p.m. ET on Wednesday, April 13, 2016 in New York City.
CEMP: 21.94 (+0.50)
Cempra Reports Positive Data on Antibiotic Solithromycin
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 1:10PM CST
Cempra (CEMP) announced positive results from the phase III SOLITAIRE-ORAL study on solithromycin for the treatment of community-acquired bacterial pneumonia.
AGN: 238.00 (+3.46), LGND: 103.31 (-1.00), CEMP: 21.94 (+0.50), SNY: 38.47 (unch)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctt3q8/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionsand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Resistant Staphylococcus Aureus (MRSA) InfectionsOverview - Therapeutics Development - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview - Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development Companies Mentioned - Absynth Biologics Limited - Adenium Biotech ApS - AIMM Therapeutics B.V. - Alchemia Limited - Allergan Plc - AlphaMab Co., Ltd - Alvogen Korea - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Aphios Corporation - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bharat Biotech International Limited - BioDiem Ltd - BioSource Pharm, Inc. - C3 Jian, Inc - Cellceutix Corporation - Cempra, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - CSA Biotechnologies LLC - Debiopharm International S.A. - DesignMedix, Inc. - Destiny Pharma Limited - Dong-A Socio Group - Ensol Biosciences Inc. - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - Ildong Pharmaceutical Co., Ltd. - Immupharma Plc - ImmuVen, Inc. - iNtRON Biotechnology Inc. For more information visit http://www.researchandmarkets.com/research/ct...llinresist
AGN: 238.00 (+3.46), AZN: 32.81 (unch), CEMP: 21.94 (+0.50), APHB: 1.70 (-0.01), GLPG: 54.30 (-0.55)
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra's Oral Solithromycin in Community-Acquired Bacterial Pneumonia
GlobeNewswire - Fri Feb 05, 6:00AM CST
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone
CEMP: 21.94 (+0.50)
